Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications.

[1]  S. Rosenberg,et al.  Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. , 1990, Journal of immunology.

[2]  S. Rosenberg,et al.  Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. , 1989, Cancer research.

[3]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[4]  J. Whitton,et al.  Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes , 1989, The Journal of experimental medicine.

[5]  S. Rosenberg,et al.  IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. , 1989, Journal of immunology.

[6]  A. Belldegrun,et al.  Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. , 1989, Journal of immunology.

[7]  S. Rosenberg,et al.  IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. , 1989, Journal of immunology.

[8]  S. Meuer,et al.  LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION , 1989, The Lancet.

[9]  L. Hood,et al.  The T-cell receptor repertoire and autoimmune diseases. , 1989, Annual review of immunology.

[10]  F. Ognibene,et al.  Cardiorespiratory effects of immunotherapy with interleukin-2. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[12]  S. Rosenberg,et al.  Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma , 1988, The Journal of experimental medicine.

[13]  S. Goyert,et al.  The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. , 1988, Journal of immunology.

[14]  M. Atkins,et al.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. , 1988, The New England journal of medicine.

[15]  C. Figdor,et al.  Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. , 1988, Journal of immunology.

[16]  S. Rosenberg,et al.  Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. , 1987, Journal of immunology.

[17]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[18]  M. Papa,et al.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Papa,et al.  Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. , 1986, Cancer research.

[20]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[21]  T. Mak,et al.  Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer , 1985, Nature.

[22]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. , 1985, Journal of immunology.

[23]  P. Hersey,et al.  Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. , 1983, British Journal of Cancer.

[24]  M C Berenbaum,et al.  Criteria for analyzing interactions between biologically active agents. , 1981, Advances in cancer research.

[25]  A. Breckenridge.  Hypertension and hyperuricaemia. , 1966, Lancet.